Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
This article was originally published in STAT.
For manufacturers, building a static commercialization strategy will only take you so far. But infusing that strategy with real-world data (RWD) — consisting of medical…
Since the passing of the Inflation Reduction Act (IRA) last fall, pharma companies have been bracing for the impact of its provisions. The main healthcare-related IRA policies are the out-of-pocket…
In the past few years, real-world data (RWD) has become an increasingly important element of a successful market access strategy. By blending claims and lab data with clinical pathway and…
In the past, rare disease manufacturers often assumed that any therapy they launched would automatically be covered by most health plans. But the rising cost of many rare disease drugs…
Since the passing of the Inflation Reduction Act (IRA) in August 2022, the healthcare industry has been bracing for the impact of several key provisions. Three of these policies—price negotiations,…
This article was originally published in BioPharma Dive.
Over the past few decades, pharma companies have perfected the art of using market access data to support product launches, negotiate payer…
Biotech and pharma companies have a vast range of capabilities and data sophistication, from their data acquisition strategy down to the way they consume, curate and present data internally.
In…
According to the National Institutes of Health (NIH), approximately 80% of research studies fail to meet their enrollment goals within the stated timeframes. Recruitment and trial design challenges can prolong…
This article was originally published in BioPharma Dive.
In the competitive pharma marketplace, physician engagement plays a critical role in a drug manufacturer’s commercialization strategy. However, before manufacturers can promote…
